Navigation Links
TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Date:6/23/2008

LA JOLLA, Calif., June 23 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that Dr. Neil Kurtz, President and Chief Executive Officer, will present data obtained from the Phase IIb study that evaluated the safety, tolerability and efficacy of three doses of tezampanel given subcutaneously for treatment of acute migraine at the 50th Annual Scientific Meeting of the American Headache Society in Boston on Saturday, June 28th at 2:00pm, Eastern.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity and rigidity, xerostomia and cognitive disorders. The company is currently developing four product candidates: two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at http://www.torreypinestherapeutics.com.

Company Contact: Media Contact:

Paul Schneider David Schull

TorreyPines Therapeutics, Inc. Russo Partners, LLC

858-623-5665, x125 212-845-4271

pschneider@torreypinestherapeutics.com david.schull@russopartnersllc.com

Investor Contact:

Rhonda C
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
2. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
3. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
4. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
5. TorreyPines Therapeutics Reports Third Quarter 2007 Results
6. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
8. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
9. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
10. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
11. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY ) ... shares of its Common Stock and Series A Convertible ... The Series A Convertible Preferred Stock is non-voting and ... conversion will be prohibited if, as a result, the ... 4.99% of the Common Stock then outstanding. As part ...
(Date:9/17/2014)... Sept. 17, 2014  MiMedx Group, Inc. (NASDAQ: ... marketer of patent protected regenerative biomaterials and bioimplants ... of another peer-reviewed clinical study.    ... Randomized Controlled Clinical Trial Evaluating the Use of ... and Multi-layer Compression Therapy vs. Multi-layer Compression Therapy ...
(Date:9/17/2014)... & Rockville, MD (PRWEB) September 17, 2014 ... a Small Business Innovation Research (SBIR) grant to support ... The award will provide ITI with approximately $255,000 over ... nuts, a leading cause of food allergy, affect over ... of anaphylaxis behind peanut allergy. Tree nut exposure is ...
(Date:9/17/2014)... 17, 2014 Alternative Fuels Americas, Inc. (AFAI) announced ... Special Purpose Vehicle in partnership with Jatro Greentech, Inc., a ... company. The SPV shall be called AFAI Jatro Green Ethiopia ... majority shareholder. The SPV shall pursue Jatropha planting and biofuels ... Ethiopia . "Although we have ...
Breaking Biology Technology:Oncothyreon Announces Proposed Public Offerings 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3
... is pleased to announce that they have acquired ... fully diluted basis. The cash consideration,will be used ... further develop,its technology., Molecular Vision is developing ... that will greatly extend the in-house tools,available to ...
... Inc.,(Nasdaq: VTIV ) today announced that Eran ... Officer, will make a presentation at the,2008 UBS ... which will,be held February 11-13, 2008. The conference ... management presentations and,extensive Q&A opportunities., inVentiv,s presentation ...
... loss of some top,talent, including Lipitor pioneer Dr. ... teaming to help speed research to fight bone ... arthritis and,osteoporosis., Velcura Therapeutics President and CEO ... work with Dr. Sliskovic and International,Discovery Sourcing Consultants, ...
Cached Biology Technology:Acrongenomics Acquires Equity Stake in Molecular Vision 2Acrongenomics Acquires Equity Stake in Molecular Vision 3inVentiv Health to Present at the 2008 UBS Global Healthcare Services Conference 2Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease 2
(Date:9/17/2014)... Kingdom forms a new crime unit designed to fight ... year over horse meat being passed off as beef ... detecting meat adulteration. They describe their approach, which represents ... Journal of Agricultural and Food Chemistry . , Hans-Ulrich ... major global economic problem. But they also say that ...
(Date:9/16/2014)... for Children,s Environmental Health at the Mailman School of ... between childhood asthma and prenatal exposure to two phthalates ... appear online in the journal Environmental Health Perspectives ... pregnancy to higher levels of the chemicals, butylbenzyl phthalate ... and 78 percent increase in risk of developing asthma ...
(Date:9/16/2014)... 2014)More than $100 trillion in cumulative public and ... dioxide (CO2)a 40 percent reduction of urban passenger ... world expands public transportation, walking and cycling in ... the University of California, Davis, and the Institute ... Further, an estimated 1.4 million early deaths could ...
Breaking Biology News(10 mins):Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5
... University doctoral candidate and a National Park Service researcher ... , J. Judson "Jut" Wynne, an NAU graduate student ... Biological Science Center, and Kyle Voyles from Parashant National ... in northwestern Arizona. , The still-unnamed genus of cave ...
... living on mineral water, the glassy-winged sharpshooter consumes only ... which is feverishly working to prevent the insect's flight ... study published in the June 6 issue of Public ... Institute for Genomic Research (TIGR), the University of Arizona, ...
... approaches to genetic disease, based on cells' own ability to ... at the annual conference of the European Society of Human ... Instead of replacing a faulty gene (commonly referred to as ... therapeutic potential that already exists in human biology. , Professor ...
Cached Biology News:NAU researchers chirping over discovery of new cricket genus 2NAU researchers chirping over discovery of new cricket genus 3Surprising symbiosis: Glassy-winged sharpshooter eats with friends 2Surprising symbiosis: Glassy-winged sharpshooter eats with friends 3'Smart' genetic therapy helps the body to heal itself 2'Smart' genetic therapy helps the body to heal itself 3'Smart' genetic therapy helps the body to heal itself 4
... This personal-sized Thermal Cycler is the ideal ... a full range of PCR applications. ... affordable price. Save lab space without ... software. Industry-Standard PCR Technology You Can ...
... Salmonella typhimurium The genus Salmonella is a ... composed of Gram-negative bacilli that are facultative and ... "H" or flagellar antigen (phase 1 & 2), ... LPS moiety) and the "Vi" or capsular antigen ...
... With 36 mg/L sodium pyruvate, 50 ... 1000 mg/L glucose, calcium chloride, and magnesium ... solution (BSS) in tissue culture is generally ... In 1885, Sydney Ringer developed a solution ...
... micro 1 is a dramatic breakthrough in accurate, ... with 10nL resolution, the micro 1 has unique ... And, the micro 1 never needs re-calibration as ... Screen programming on an LCD Display , Graphical ...
Biology Products: